Woonyoung Choi1, Andrea Ochoa1, David J McConkey2, Mattias Aine3, Mattias Höglund3, William Y Kim4, Francisco X Real5, Anne E Kiltie6, Ian Milsom7, Lars Dyrskjøt8, Seth P Lerner9. 1. Department of Urology, U.T. M.D. Anderson Cancer Center, Houston, Texas, USA; Department of Cancer Biology, U.T. M.D. Anderson Cancer Center, Houston, Texas, USA. 2. Department of Urology, U.T. M.D. Anderson Cancer Center, Houston, Texas, USA; Department of Cancer Biology, U.T. M.D. Anderson Cancer Center, Houston, Texas, USA. Electronic address: djmcconkey@jhmi.edu. 3. Division of Oncology and Pathology, Department of Clinical Sciences, Faculty of Medicine, Lund University, Lund, Sweden. 4. University of North Carolina, Chapel Hill, North Carolina, USA. 5. Epithelial Carcinogenesis Group, Spanish National Cancer Research Centre-CNIO, Madrid, Spain; Departament de Ciències Experimentalsi de la Salut, Universitat Pompeu Fabra, Barcelona, Spain. 6. Department of Oncology, University of Oxford, Oxford, UK. 7. Institute of Clinical Sciences, Sahlgrenska Academy at Gothenburg University, Gothenburg, Sweden. 8. Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark. 9. TCGA Analysis Working Group, Baylor College of Medicine, Houston, Texas, USA.
Abstract
CONTEXT: Recent whole genome mRNA expression profiling studies revealed that bladder cancers can be grouped into molecular subtypes, some of which share clinical properties and gene expression patterns with the intrinsic subtypes of breast cancer and the molecular subtypes found in other solid tumors. The molecular subtypes in other solid tumors are enriched with specific mutations and copy number aberrations that are thought to underlie their distinct progression patterns, and biological and clinical properties. OBJECTIVE: The availability of comprehensive genomic data from The Cancer Genome Atlas (TCGA) and other large projects made it possible to correlate the presence of DNA alterations with tumor molecular subtype membership. Our overall goal was to determine whether specific DNA mutations and/or copy number variations are enriched in specific molecular subtypes. EVIDENCE: We used the complete TCGA RNA-seq dataset and three different published classifiers developed by our groups to assign TCGA's bladder cancers to molecular subtypes, and examined the prevalence of the most common DNA alterations within them. We interpreted the results against the background of what was known from the published literature about the prevalence of these alterations in nonmuscle-invasive and muscle-invasive bladder cancers. EVIDENCE SYNTHESIS: The results confirmed that alterations involving RB1 and NFE2L2 were enriched in basal cancers, whereas alterations involving FGFR3 and KDM6A were enriched in luminal tumors. CONCLUSIONS: The results further reinforce the conclusion that the molecular subtypes of bladder cancer are distinct disease entities with specific genetic alterations. PATIENT SUMMARY: Our observation showed that some of subtype-enriched mutations and copy number aberrations are clinically actionable, which has direct implications for the clinical management of patients with bladder cancer.
CONTEXT: Recent whole genome mRNA expression profiling studies revealed that bladder cancers can be grouped into molecular subtypes, some of which share clinical properties and gene expression patterns with the intrinsic subtypes of breast cancer and the molecular subtypes found in other solid tumors. The molecular subtypes in other solid tumors are enriched with specific mutations and copy number aberrations that are thought to underlie their distinct progression patterns, and biological and clinical properties. OBJECTIVE: The availability of comprehensive genomic data from The Cancer Genome Atlas (TCGA) and other large projects made it possible to correlate the presence of DNA alterations with tumor molecular subtype membership. Our overall goal was to determine whether specific DNA mutations and/or copy number variations are enriched in specific molecular subtypes. EVIDENCE: We used the complete TCGA RNA-seq dataset and three different published classifiers developed by our groups to assign TCGA's bladder cancers to molecular subtypes, and examined the prevalence of the most common DNA alterations within them. We interpreted the results against the background of what was known from the published literature about the prevalence of these alterations in nonmuscle-invasive and muscle-invasive bladder cancers. EVIDENCE SYNTHESIS: The results confirmed that alterations involving RB1 and NFE2L2 were enriched in basal cancers, whereas alterations involving FGFR3 and KDM6A were enriched in luminal tumors. CONCLUSIONS: The results further reinforce the conclusion that the molecular subtypes of bladder cancer are distinct disease entities with specific genetic alterations. PATIENT SUMMARY: Our observation showed that some of subtype-enriched mutations and copy number aberrations are clinically actionable, which has direct implications for the clinical management of patients with bladder cancer.
Authors: Floris H Groenendijk; Jeroen de Jong; Elisabeth E Fransen van de Putte; Magali Michaut; Andreas Schlicker; Dennis Peters; Arno Velds; Marja Nieuwland; Michel M van den Heuvel; Ron M Kerkhoven; Lodewijk F Wessels; Annegien Broeks; Bas W G van Rhijn; René Bernards; Michiel S van der Heijden Journal: Eur Urol Date: 2015-01-27 Impact factor: 20.096
Authors: Jordan Kardos; Shengjie Chai; Lisle E Mose; Sara R Selitsky; Bhavani Krishnan; Ryoichi Saito; Michael D Iglesia; Matthew I Milowsky; Joel S Parker; William Y Kim; Benjamin G Vincent Journal: JCI Insight Date: 2016-03-17
Authors: Jonathan E Rosenberg; Jean Hoffman-Censits; Tom Powles; Michiel S van der Heijden; Arjun V Balar; Andrea Necchi; Nancy Dawson; Peter H O'Donnell; Ani Balmanoukian; Yohann Loriot; Sandy Srinivas; Margitta M Retz; Petros Grivas; Richard W Joseph; Matthew D Galsky; Mark T Fleming; Daniel P Petrylak; Jose Luis Perez-Gracia; Howard A Burris; Daniel Castellano; Christina Canil; Joaquim Bellmunt; Dean Bajorin; Dorothee Nickles; Richard Bourgon; Garrett M Frampton; Na Cui; Sanjeev Mariathasan; Oyewale Abidoye; Gregg D Fine; Robert Dreicer Journal: Lancet Date: 2016-03-04 Impact factor: 79.321
Authors: Claire F Taylor; Fiona M Platt; Carolyn D Hurst; Helene H Thygesen; Margaret A Knowles Journal: Hum Mol Genet Date: 2013-11-22 Impact factor: 6.150
Authors: Seth P Lerner; David J McConkey; Katherine A Hoadley; Keith S Chan; William Y Kim; François Radvanyi; Mattias Höglund; Francisco X Real Journal: Bladder Cancer Date: 2016-01-07
Authors: N Vasdev; H Zargar; J P Noël; R Veeratterapillay; A S Fairey; L S Mertens; C P Dinney; M C Mir; L M Krabbe; M S Cookson; N E Jacobsen; N M Gandhi; J Griffin; J S Montgomery; E Y Yu; E Xylinas; N J Campain; W Kassouf; M A Dall'Era; J A Seah; C E Ercole; S Horenblas; S S Sridhar; J S McGrath; J Aning; S F Shariat; J L Wright; T M Morgan; T J Bivalacqua; S North; D A Barocas; Y Lotan; P Grivas; A J Stephenson; J B Shah; B W van Rhijn; S Daneshmand; P E Spiess; J M Holzbeierlein; A Thorpe; P C Black Journal: World J Urol Date: 2018-06-07 Impact factor: 4.226
Authors: Jason A Efstathiou; Kent W Mouw; Ewan A Gibb; Yang Liu; Chin-Lee Wu; Michael R Drumm; Jose Batista da Costa; Marguerite du Plessis; Natalie Q Wang; Elai Davicioni; Felix Y Feng; Roland Seiler; Peter C Black; William U Shipley; David T Miyamoto Journal: Eur Urol Date: 2019-02-01 Impact factor: 20.096
Authors: Daley S Morera; Sarrah L Hasanali; Daniel Belew; Santu Ghosh; Zachary Klaassen; Andre R Jordan; Jiaojiao Wang; Martha K Terris; Roni J Bollag; Axel S Merseburger; Arnulf Stenzl; Mark S Soloway; Vinata B Lokeshwar Journal: J Urol Date: 2019-05-21 Impact factor: 7.450
Authors: Laura-Maria Krabbe; Vitaly Margulis; Andres Jan Schrader; Shahrokh F Shariat; Kilian M Gust; Martin Boegemann Journal: World J Urol Date: 2018-06-08 Impact factor: 4.226
Authors: Izak Faiena; Amirali Salmasi; Neil Mendhiratta; Andrew T Lenis; Aydin Pooli; Alexandra Drakaki; Kiran Gollapudi; Jeremy Blumberg; Allan J Pantuck; Karim Chamie Journal: World J Urol Date: 2018-05-11 Impact factor: 4.226